SCHEDULE: Federated Hermes Discloses 8.78% Passive Stake in Forte Biosciences

Federated Hermes, Inc. and affiliated entities have disclosed a passive beneficial ownership of 8.78% in Forte Biosciences, Inc. common stock as of June 30, 2025.

Summary

• Federated Hermes, Inc., along with its subsidiaries and the Voting Shares Irrevocable Trust, collectively hold 1,072,233 shares of Forte Biosciences, Inc. common stock.
• This aggregate amount represents 8.78% of the total class of Forte Biosciences, Inc. common stock.
• Federated Hermes, Inc. and the Voting Shares Irrevocable Trust, including its trustees Thomas R. Donahue, Ann C. Donahue, and J. Christopher Donahue, are the reporting persons.
• The shares are held with sole voting and sole dispositive power by Federated Hermes, Inc. and the Voting Shares Irrevocable Trust, while the individual trustees share voting and dispositive power over the same shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose or effect of changing or influencing the control of Forte Biosciences, Inc.

Sentiment

Score: 6

Explanation: The disclosure of a significant passive stake by a reputable institutional investor like Federated Hermes can be viewed as a positive signal of confidence in the company, even with the standard disclaimer of beneficial ownership.

Positives

• The disclosure of a significant 8.78% stake by a major institutional investor like Federated Hermes, Inc. may signal confidence in Forte Biosciences, Inc. from a prominent asset manager.

Future Outlook

NA

Management Comments

• Federated Hermes, Inc. certifies that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.
• The reporting persons, including Federated Hermes, Inc., the Voting Shares Irrevocable Trust, and the Trustees, declare that the statement should not be construed as an admission that they are the beneficial owners of the Reported Securities and expressly disclaim beneficial ownership of the Reported Securities.

Industry Context

Schedule 13G filings are routine disclosures by institutional investors who acquire more than 5% of a company's voting shares with a passive investment intent. This filing indicates that Federated Hermes, Inc. and its affiliates have taken a significant, non-controlling stake in Forte Biosciences, Inc., which is a common practice for large asset managers investing on behalf of their clients.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by Federated Hermes may be perceived positively, potentially indicating increased institutional interest and confidence in Forte Biosciences, Inc.

Key Dates

Keywords

Forte Biosciences, Federated Hermes, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Passive Investment